Research and Publications

Inotek has published the results and analysis of its Phase 1 and Phase 2 trabodenoson monotherapy clinical trials in the October 2016 issue of the Journal of Ocular Pharmacology and Therapeutics. We have also presented our research at several ophthalmology and glaucoma congresses, including the American Glaucoma Society annual meeting (AGS), the Association for Research in Vision and Ophthalmology annual meeting (ARVO), the Ophthalmology Innovation Summit at the American Academy of Ophthalmology annual meeting (OIS@AAO) and the International Symposium on Ocular Pharmacology and Therapeutics (ISOPT).

Read our articles:

A Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult Volunteers

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 and 4 Weeks of Twice-Daily Ocular Trabodenoson in Adults with Ocular Hypertension or Primary Open-Angle Glaucoma

View select posters and presentations:

2017 AGS Poster: Further elucidation of the mechanism of action of trabodenoson using 3D-human trabecular meshwork constructs

2017 AGS Poster: Incidence of hyperemia in the trabodenoson monotherapy clinical development program through Phase 2

2017 AGS Poster: Improved function of retinal ganglion cells by topically administered trabodenoson in a rat model of optic nerve crush injury

2016 OIS@AAO Presentation: “Transforming Glaucoma Treatments”